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IntroductIon
Rarely in human disease can a single host 
factor be identified as the primary causal 
factor of a disease, syndrome, or disorder. 
Rather, the clinical manifestations that cul-
minate in a symptomatic state are usually 
triggered by a perturbation of multiple fac-
tors derived from several distinct, but inte-
grated, domains of cellular regulation. Host 
immune responses, such as antimicrobial 
peptide (AMP) production and regulation, 
are the result of interdependent dynamic 
interactions between host cells, extracel-
lular milieu, and the external environ-
ment. In order to truly elucidate disease 
pathogenesis, it is imperative to consider 
the entire system at play from a global per-
spective, which is the promise of “omics” 
technology. The term “omics” was originally 
coined as a discipline in molecular biology 
that examines global sets of biological mol-
ecules (Micheel et al., 2012), which conse-
quently stimulated an “Omics Revolution” 
throughout the scientific community. 
Genomics emerged following the sequenc-
ing of the human genome in the 1990s 
and early 2000s. This subsequently led to 
proteomics, which includes the entire com-
plement of proteins and their related struc-
ture, modifications, and function. Pauling 
et al. (1971) proposed that estimating the 
abundance of metabolites in biological flu-
ids may indicate the functional status of a 
specific biological system. Consequently, 
metabolomics has recently surfaced as an 
approach to comprehensively identify and 
quantify low molecular weight exogenous 
and endogenous metabolites and com-
pounds in a biological system using high-
throughput methods. Using 16S rRNA gene 
sequencing tools originally developed in the 
field of environmental microbiology, we can 
now generate a site-specific  microbiome 
profile for any given patient. The Human 
Microbiome Project and numerous other 
projects aim to discern relationships 
between human-associated microbes and 
health and disease (Zoetendal et al., 2006). 
Such research has generated massive and 
complex data sets, which requires further 
advancement and refinement of bioin-
formatics and biostatistical applications. 
Often, the data is used to produce com-
putational models to distinguish specific 
characteristics of a given population. Due to 
the unavoidable complexities and required 
statistical sophistication, few medical fields 
have developed clinically useful applications 
for the resulting data. Thus, AMPs are an 
ideal set of biological molecules to assess, 
since there biological role spans numerous 
areas of clinical research.
Due to their diverse microbicidal 
and immunomodulatory functions 
(Steinstraesser et al., 2011), AMPs com-
prise a major aspect of the host innate 
immune response (Nakatsuji and Gallo, 
2012). Alterations in AMP production and/
or localization are associated with several 
cutaneous dermatoses. Patients diagnosed 
with atopic dermatitis and psoriasis ulti-
mately develop epidermal barrier defects 
and microbial susceptibility, or a hyperpro-
liferative/inflammatory epidermis, respec-
tively (Schauber and Gallo, 2008; Schroder, 
2011). The contributions of AMPs to tis-
sue integrity and epithelial defense was 
also established in the brain (Schluesener 
et al., 2012; Williams et al., 2012), uri-
nary tract (Saemann et al., 2007; Zasloff, 
2007; Ali et al., 2009), gastrointestinal tract 
(Lisitsyn et al., 2012), and certain malignan-
cies (Kesting et al., 2012; Scola et al., 2012). 
However, altered AMP regulation does not 
occur exclusively, but instead embodies 
dynamic transformations that emerge as a 
disturbed system. The integration of several 
different “omics” techniques may provide a 
more complete understanding of the diverse 
factors contributing to a specific disease 
state, responses to pharmacologic agents, 
or novel alternatives to current treatment 
modalities.
AMPs As A dIseAse MArker
The appeal of “omics” research lies in the 
possibility of identifying an AMP profile 
that distinguishes one particular patient 
in a clinically useful manner to categorize 
them as high- or low-risk for developing 
a post-operative infection (e.g., pneumo-
nia). Several studies have demonstrated 
the importance of cathelicidin (Braff et al., 
2007; Kovach et al., 2012), beta-defensins 
(Chong et al., 2008; Scharf et al., 2012), and 
several other AMPs in regulating epithelial 
immunity (Cole and Waring, 2002; Tecle 
et al., 2010). Consequently, it is feasible 
that integrating these variables simultane-
ously may reveal unexplored or intriguing 
connections, and likely identify invaluable 
correlations that are clinically significant.
Antimicrobial peptides have been exten-
sively evaluated for their role in inflam-
mation (Lai and Gallo, 2009), while little 
research has investigated their potential role 
in rejection following organ transplanta-
tion. Although these patients are typically 
immunosuppressed, abnormal alterations 
in AMPs following transplantation may 
contribute to or serve as a marker of inflam-
mation and rejection. A diagnostic tool to 
yield a molecular AMP profile of a trans-
plant patient could serve as a prognostic 
indicator of organ failure. Nuclear mag-
netic resonance (NMR) based metabolomic 
technologies have also attempted to identify 
other urine biomarkers as an indicator of 
chronic renal failure and renal transplant 
Integrating “omics” technologies to conceptualize dynamic 
antimicrobial peptide responses
Jennifer K. Plichta, Vanessa Nienhouse and Katherine A. Radek*
Department of Surgery, Burn and Shock Trauma Institute, Loyola University Health Systems, Maywood, IL, USA
*Correspondence: kradek1@lumc.edu
Edited by:
Mark W. Robinson, Queen’s University Belfast, Northern Ireland
Reviewed by:
Andrew T. Hutchinson, University of Technology Sydney, Australia
www.frontiersin.org September 2012 | Volume 3 | Article 284 | 1
OpiniOn Article
published: 17 September 2012
doi: 10.3389/fimmu.2012.00284
function (Bell et al., 1991; Foxall et al., 1993). 
Similar technologies could be employed to 
identify how AMPs may correlate with clini-
cal outcomes in transplant patients. In com-
parison, trauma and burn patients exhibit 
profound defects in immune regulation 
following injury, including perturbations 
in AMPs (Steinstraesser et al., 2004; Bhat 
and Milner, 2007). A diagnostic AMP profile 
may again provide invaluable data to predict 
healing, immune integrity, or graft survival. 
The clinical utility of such targeted profiles 
could undoubtedly be applied to numer-
ous disease states involving infection and/
or inflammation, to serve as markers of 
prognosis.
Currently, NMR and Mass Spectrometry 
are two major platforms by which metabo-
lomic analyses are evaluated via bioinfor-
matic tools. Several skin AMPs were recently 
implicated in tumorigenesis of cutaneous 
squamous cell carcinoma (Scola et al., 
2012). Significant metabolic alterations 
usually ensue as normal cells are trans-
formed into a malignant phenotype. Using 
a limited rationale, AMPs may simply reflect 
alterations in the local environment from 
the presence of the malignancy, or may sim-
ply be irrelevant to the malignancy. A more 
sophisticated rationale suggests that altera-
tions in AMPs may serve as a biomarker for 
disease severity and/or progression, and 
denote a significant underlying process that 
contributes to a malignancy. Interestingly, 
the wound repair process and cancer pro-
gression are both associated with alterations 
in the inflammatory/immune microenvi-
ronment. During wound repair, AMPs are 
released from epithelial and infiltrating 
immune cells to stimulate re-epithelializa-
tion, new vessel formation, and extracellu-
lar matrix (ECM) remodeling (Radek and 
Gallo, 2007). However, the dynamics of 
cancer progression and tissue repair differ 
in that wound healing is a self-limiting pro-
cess, while tumor formation is characterized 
by a continuous, uncontrolled activation 
of similar pathways that facilitate tumor 
growth and metastasis. One key observation 
is that prominent associations exist between 
the cytokines, chemokines, and growth fac-
tors present in healing wounds and wound 
fluid, as compared to tumors. In parallel, a 
striking difference in the temporal regula-
tion of these factors was determined by the 
combination of several genomic technolo-
gies (Pedersen et al., 2003). Furthermore, 
proteomics and genomic methods are 
now being employed through a multidis-
ciplinary translational research approach 
to improve the bioactive components in 
matrix therapies for non-healing wounds to 
specifically modulate the temporal and local 
release of these micromolecules (Sweitzer 
et al., 2006). Degradomics is emerging in 
the wound healing field as a new technol-
ogy that assimilates the current knowledge 
database of ECM regulation and deciphers 
the complex interactions between proteases 
and their respective inhibitors using systems 
biology as a means to improve wound integ-
rity in chronic wounds (Hermes et al., 2011). 
Since AMPs are an integral part of wound 
healing and inflammation, the knowledge 
gained from utilizing these evolving “omics” 
technologies may be extrapolated to other 
dimensions of data analysis that span other 
disease states which share similar mecha-
nisms of disease progression.
Antimicrobial peptide regulation can 
clearly modulate and be influenced by the 
composition of the microbial flora of the 
human host. Several AMPs are induced in 
response to both invasive pathogens, as well 
as commensal strains of bacteria to gener-
ate specific down-stream innate or adaptive 
immune signaling events. For instance, the 
cutaneous commensal Staphylococcus epi-
dermidis induces human β-defensin-2 and 
-3 via a TLR-2 signaling dependent mecha-
nism (Lai et al., 2010). This interaction is 
beneficial for both the host and microbe by 
facilitating the eradication of pathogens on 
the skin via AMP induction, while simul-
taneously allowing S. epidermidis to fur-
ther proliferate with fewer competitors for 
metabolic resources. Further complicating 
these interactions, microbes have evolved 
several mechanisms to evade host AMPs 
via altered cell surface charge, efflux trans-
porters, proteases, or trapping proteins, and 
direct adaptations of host cellular processes 
(Nizet, 2006). These dynamic interactions 
between the host and the resident micro-
biota can significantly influence the overall 
homeostatic balance.
The integration of multiple “omics” 
disciplines is applicable to several tangi-
ble clinical situations where infection is a 
risk factor. For example, identification of 
patients most at risk for a urinary tract 
infection (UTI) would improve prophylac-
tic therapies for susceptible patient popu-
lations, including burn-injured, surgical, 
or bedridden individuals. Recent studies 
deliver a long overdue confirmation that 
urine is not sterile, which challenges the 
current dogma (Nelson et al., 2010; Dong 
et al., 2011; Wolfe et al., 2012). Thus, inte-
gration of multiple “omics” technologies, 
such as 16S rRNA gene sequencing and pro-
teomics, may identify correlations between 
specific AMPs and distinct genera of bac-
teria to identify unique patterns that could 
be employed as a diagnostic tool to predict 
those individuals who may be at a higher 
risk for a UTI. Furthermore, the develop-
ment of a rapid, high-throughput assay that 
integrates multiple “omics” technologies to 
correlate AMPs with tissue specific micro-
biota would be invaluable to clinicians for 
prediction of UTI or other disease states.
AMPs As A therAPeutIc tArget
Aside from patient-centered applications, 
AMP-related “omics” research is also being 
utilized in drug discovery, as AMPs have 
been targeted as a potential alternative 
to conventional antibiotics by serving as 
adjuncts and/or replacements to tradi-
tional antibiotics, although more research 
is clearly needed to develop these promising 
tools (Hirsch et al., 2008; Baltzer and Brown, 
2011; Ahmad et al., 2012; Hassan et al., 
2012). Infection remains a leading cause of 
death in the US, with influenza/pneumonia 
and septicemia both ranking in the top 15 
(Murphy et al., 2012). Several publicly avail-
able databases have already been established 
in order to collect relevant information 
related focused on AMPs (Brahmachary 
et al., 2004; Wang and Wang, 2004; Wang 
et al., 2009; Seshadri Sundararajan et al., 
2012) in order to construct models based on 
clustering and analyzing AMP sequences, 
which allow accurate recognition of spe-
cific antimicrobial classes (Fjell et al., 2007). 
Recently, a bioinformatics strategy using 
peptide sequences was employed to classify 
synthetic and endogenous AMPs based on 
their physiochemical properties to identify 
active peptides and assess antimicrobial 
potency (Kumari et al., 2012; Torrent et al., 
2012). Despite promising preliminary data, 
AMPs have yet to prove their full potential 
in clinical trials.
reseArch LIMItAtIons
It is evident that less costly and efficient high-
throughput technologies are undoubtedly 
needed to fully explore the under-utilized 
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and under-recognized potential of AMPs 
for therapeutic applications. Although 
it is feasible to capture a given patient’s 
molecular profile, the interpretation of 
those findings remains a challenge. Given 
the enormous data sets being generated by 
“omics” research, the development of useful 
computational models has been limited by 
several factors. Primarily, analyses of high-
dimensional data are prone to overfitting 
of the models to the study samples, thus 
yielding inaccurate results in subsequent 
follow-up studies. Therefore, replication 
and reproducible verification become 
imperative when performing such research. 
Prospective technological advancement 
merged with more robust bioinformatic 
tools and greater data analysis capacity will 
help surmount the existing limitations to 
allow for the complete integration of micro-
molecules with systems biology.
concLudIng reMArks
While the “Omics Revolution” continues 
to rapidly expand and mature, it is appar-
ent that its maximal applicability and util-
ity remain to be fully elucidated. “Omics” 
research, either directly examining AMPs 
or researching AMPs in the context of 
related factors such as the metabalome or 
the microbiome, could potentially iden-
tify significant and crucial relationships 
between various molecular signatures and 
human disease (Figure 1). These enormous 
data sets may serve as the foundation for 
the evolution of computational models 
that could predict disease, complications, 
or even prognosis based on a specific AMP 
profile. Furthermore, modified AMPs have 
the potential to replace current antibiotic 
therapies, as drug discovery begins incor-
porating the latest technology into their 
pharmaceutical development pipelines. 
Ultimately, the new approach to personal-
ize healthcare can foster novel applications 
to refine the characterization of a disease 
phenotype, identify predictive biomarkers, 
determine the efficacy of various therapies, 
or determine the susceptibility to drug tox-
icity for each individual patient.
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